VIVUS Inc

VIVUS — Technical Presentation (August 2010)

12 slides from VIVUS's technical presentation, Aug 2, 2010

  1. Slide 1: Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American vs Non-African American Subjects

    A. Julian Muñoz, MD University of Michigan W. Timothy Garvey, MD University of Alabama at Birmingham Wesley W. Day, PhD Vivus, Inc. Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate in African American Subjects vs Non-African American Subjects: Pooled 1-Year Data From Two Phase 3

  2. Slide 2: Author Disclosure

    Author Disclosure A. Julian Muñoz No relationships to disclose W. Timothy Garvey Research support – Merck & Co., Inc.; Isis/Genzyme; Amylin Pharmaceuticals Speakers Bureau – Merck & Co., Inc; Abbott Nutrition Advisor/consultant – Daiichi-Sankyo; Tethys; Vivus, Inc. Board member – Daiichi-Sankyo, Tet

  3. Slide 3: Background

    Background Obesity is associated with significantly increased morbidity, mortality related to cardiovascular disease, diabetes1,2 NHANES data show disproportionate prevalence across ethnic/racial groups:3 African American (AA) population: 44.1% Hispanic/Latino population: 37.9% Caucasian population:

  4. Slide 4: Objectives

    Objectives To evaluate weight loss over a 56-week period in overweight/obese subjects To evaluate weight loss in AA subjects and non-AA subjects over 56 weeks

  5. Slide 5: Methods

    Methods Pooled 1-year data from two randomized, double-blind, 56-week Phase 3 trials EQUIP: N=1267 obese nondiabetic subjects (BMI >35 kg/m2): Placebo n=514 PHEN 3.75 mg/TPM CR 23 mg (3.75/23) n=241 PHEN 15 mg/TPM CR 92 mg (15/92) n=512 CONQUER: N=2487 overweight/obese adult subjects (BMI >27 kg/m2

  6. Slide 6: Assessments

    Assessments Primary endpoint: Percent weight loss* Prespecified secondary endpoint: Percentage of subjects with >10% weight loss at 56 weeks* Secondary analysis: Pooled 1-year data conducted to determine differences in efficacy and safety between AA and non-AA subjects *Analysis of percent weight lo

  7. Slide 7: Baseline Characteristics from Pooled 1-Year Analysis of EQUIP and CONQUER (ITT)

    Baseline Characteristics from Pooled 1-Year Analysis of EQUIP and CONQUER (ITT) Placebo (n=1477) PHEN/TPM CR 3.75/23 (n=234) 7.5/46 (n=488) 15/92 (n=1479) Age (years), mean (SD) 48.5 (11.43) 43.0 (11.05) 51.1 (10.38) 48.0 (11.97) Female, n (%) 1102 (74.6) 194 (82.9) 341 (69.9) 1094 (74.0) Ethnicity,

  8. Slide 8: Percent Weight Change at 56 Weeks (ITT-LOCF)

    *P<0.0001 vs placebo; †P=0.0236 vs placebo Percent Weight Change at 56 Weeks (ITT-LOCF) Baseline (kg) 107 119 103 107 112 128 106 111 107 117 102 107

  9. Slide 9: Subjects With >10% Weight Loss at Week 56 (ITT-LOCF)

    *P<0.0001 vs placebo; †P=0.0215 vs placebo Subjects With >10% Weight Loss at Week 56 (ITT-LOCF) Baseline (kg) 107 119 103 107 112 128 106 111 107 117 102 107

  10. Slide 10: Treatment-Emergent Adverse Events, Discontinuation and Completion Rates

    Treatment-Emergent Adverse Events (TEAEs), Discontinuation and Completion Rates Safety Set (n=3749) AA Subjects Non-AA Subjects Placebo (n=206) PHEN/TPM CR (All Doses) (n=309) Placebo (n=1300) PHEN/TPM CR (All Doses) (n=1934) All TEAEs, n (%) 151 (73.3) 249 (80.6) 984 (75.7) 1673 (86.5) Severity Mil

  11. Slide 11: Safety Summary

    Safety Summary PHEN/TPM CR generally well tolerated; side effects were mostly mild to moderate in both in AA and non-AA subjects Most common TEAEs in the AA population were constipation, paresthesia, headache, and dry mouth; the most common TEAEs in the non-AA population were headache, dry mouth, an

  12. Slide 12: Conclusions

    Conclusions PHEN/TPM CR provided statistically significant, sustained, and clinically meaningful weight loss in both AA and non-AA subjects at 56 weeks PHEN/TPM CR was generally well tolerated, with most TEAEs being mild to moderate in AA and non-AA subjects Therapies that provide safe and sustained

Vivus — Technical Presentation (August 2010) on 6ix